Table 3.
Analyzed HR group | n | Hormones | X | M | SD | P |
---|---|---|---|---|---|---|
HL rtx − | 12 | FSH (mIU/mL) | 7.07 | 7.0 | 2.78 | 0.647 |
HL rtx + | 10 | 8.53 | 6.9 | 3.25 | 0.045 | |
BMT | 6 | 42.55 | 42.55 | 26.55 | 0.034 | |
Solid tumors | 9 | 10.55 | 7.9 | 14.68 | 0.068 | |
Control | 34 | 5.35 | 5.15 | 1.89 | ||
| ||||||
HL rtx − | LH (mIU/mL) | 6.13 | 3.85 | 6.67 | 0.283 | |
HL rtx + | 3.63 | 3.00 | 2.05 | 0.483 | ||
BMT | 26.31 | 15.20 | 28.23 | 0.001 | ||
Solid tumors | 6.45 | 7.0 | 5.93 | 0.494 | ||
Control | 5.52 | 4.68 | 4.1 | |||
| ||||||
HL rtx − | E2 (pg/mL) | 69.72 | 42.79 | 101.82 | 0.628 | |
HL rtx + | 47.34 | 33.09 | 32.24 | 0.578 | ||
BMT | 26.25 | 22.74 | 17.26 | 0.021 | ||
Solid tumors | 40.91 | 17.6 | 47.29 | 0.670 | ||
Control | 53.32 | 47.39 | 41.14 | |||
| ||||||
HL rtx − | AMH (pmol/L) | 23.17 | 25.10 | 15.25 | 0.042 | |
HL rtx + | 14.15 | 11.90 | 8.10 | 0.037 | ||
BMT | 3.37 | 2.62 | 2.32 | 0.001 | ||
Solid tumors | 19.21 | 8.14 | 16.30 | 0.05 | ||
Control | 27.03 | 25.26 | 12.31 |
HR: high risk, HL: Hodgkin lymphoma, rtx: radiotherapy, BMT: bone marrow transplantation, FSH: follicle-stimulating hormone, LH: luteinizing hormone, E2: estradiol, AMH: anti-Müllerian hormone, X: average value, and M: median.